OncoMatch/Clinical Trials/NCT05749289

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Is NCT05749289 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies Al18F-octreotide for sstr positive tumors.

Phase 2/3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05749289Data as of Sep 2026Location: China

Treatment: Al18F-octreotide — This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Al18F-octreotide

Biomarker criteria

Required: SSTR expression

SSTR positive tumors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05749289 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require SSTR?

Yes, SSTR expression is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify